Marc Ferrante
Experienced in Cystic Fibrosis

Dr. Marc Ferrante

Radiology
Radiation Oncology Of Southern Ct LLC
15 Corporate Dr, 
Trumbull, CT 
Experienced in Cystic Fibrosis
Radiation Oncology Of Southern Ct LLC
15 Corporate Dr, 
Trumbull, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marc Ferrante is a Radiologist in Trumbull, Connecticut. Dr. Ferrante is rated as an Experienced provider by MediFind in the treatment of Cystic Fibrosis. His top areas of expertise are Colonic Malakoplakia, ALK-Positive Non-Small Cell Lung Cancer, Gas Bloat Syndrome, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 344 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Cystic Fibrosis.

Specialties
Radiology
Licenses
Diagnostic Radiology in CT
Hospital Affiliations
St Vincent's Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Radiation Oncology of Southern Ct LLC
15 Corporate Dr, Trumbull, CT 06611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Biological
Study Drug: Vedolizumab
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
Enrollment Status: Completed
Publish Date: October 21, 2022
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: GSK2831781
Study Phase: Phase 2
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Drug: 5-HTP
Study Phase: Phase 2
View 8 Less Clinical Trials

343 Total Publications

FFAR4 drives stem cell fate toward lipid- and iron-storing enterocytes protecting human enteroids from ferroptosis.
FFAR4 drives stem cell fate toward lipid- and iron-storing enterocytes protecting human enteroids from ferroptosis.
Journal: Stem cell research & therapy
Published: September 16, 2025
Similar Doctors
Advanced in Cystic Fibrosis
Dr. Delia Keating
Radiology
Advanced in Cystic Fibrosis
Dr. Delia Keating
Radiology

MSK-Guttman Diagnostic Center

55 5th Ave, 
New York, NY 
 (33.8 miles away)
212-463-8733
Languages Spoken:
English
See accepted insurances

Delia Keating is a Radiologist in New York, New York. Dr. Keating is rated as an Advanced provider by MediFind in the treatment of Cystic Fibrosis. Her top areas of expertise are Breast Lump, Cystic Fibrosis, Lymphoid Hyperplasia, and Galactocoele.

Advanced in Cystic Fibrosis
Dr. Igor Latich
Interventional Radiology | Radiology
Advanced in Cystic Fibrosis
Dr. Igor Latich
Interventional Radiology | Radiology

Yale University

20 York St, 
New Haven, CT 
 (34.3 miles away)
203-785-4638
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Igor Latich is an Interventional Radiologist and a Radiologist in New Haven, Connecticut. Dr. Latich is rated as a Distinguished provider by MediFind in the treatment of Cystic Fibrosis. His top areas of expertise are Kimura Disease, Small Cell Lung Cancer (SCLC), Pancreatic Cancer, Embolectomy, and Osteotomy.

Experienced in Cystic Fibrosis
Dr. Lyndon Luk
Radiology
Experienced in Cystic Fibrosis
Dr. Lyndon Luk
Radiology

New York Presbyterian Hospital

177 Fort Washington Ave, 
New York, NY 
 (27.2 miles away)
212-305-2511
Languages Spoken:
English

Lyndon Luk is a Radiologist in New York, New York. Dr. Luk is rated as an Experienced provider by MediFind in the treatment of Cystic Fibrosis. His top areas of expertise are Pleural Effusion, Pleurisy, Pulmonary Fibrosis, Cholangiocarcinoma (Bile Duct Cancer), and Pancreaticoduodenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ferrante's expertise for a condition
ConditionClose
    View All 47 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile